SUMMARY
Tachycardia or hypertension after aortic surgery may be a consequence of increased concentrations of vasoactive hormones. An ot 2 -adrenergic agonist, clonidine (Catapres), has been shown to attenuate central and peripheral sympathetic and circulatory hyperactivity in several situations [1] [2] [3] [4] [5] [6] [7] [8] .
Clonidine also decreases plasma concentrations of catecholamines, vasopressin [9] and renin [10] . We have studied the effect of clonidine on vasoactive hormones and cardiovascular state after aortic surgery.
PATIENTS AND METHODS
The study was approved by the Ethics Committee and informed patient consent was obtained. On the morning of surgery, all patients with a history of hypertension (defined as an arterial pressure exceeding 160/95 mm Hg for more than 6 months), or coronary artery disease or heart failure received all their concurrent medication, including calcium entry blocking (CEB) agents. Diuretics were omitted. Patients receiving centrally-acting antihypertensives, including clonidine, were not excluded: one patient in the placebo group was receiving low dose clonidine therapy (150 ug daily). The subjects (all male) were allocated randomly in a double-blind manner to two groups before surgery by means of a random table generated by a computer. The placebo group received a normal saline infusion shortly after aortic declamping (n = 16) and the clonidine group (n = 15) received clonidine 7 |ig kg ' as an infusion of identical volume over a similar period (120 min). Two patients in the clonidine group were withdrawn from the trial for surgical reasons.
Cardiovascular data and plasma samples were collected at the following stages: immediately after vascular catheterizations and before induction of anaesthesia (baseline); immediately before infusion of clonidine (5-10 min after bilateral aortic declamping and volume replacement and cardiovascular stabilization); upon arrival in the recovery room (RR) immediately after repositioning and recalibration of the same transducer-amplifier system and treatment of any acute cardiovascular disturbance (Rl). All patients treated chronically with CEB received nifedipine 10 mg intranasally (i.n.) immediately after arrival in the recovery room. Further data and plasma samples were collected every 1 h for 5 h thereafter (R2-R6). The lungs of all patients were ventilated mechanically with 50% oxygen during the postoperative study period to a Pa COf of 4-5.3 kPa. Gases were humidified and warmed. Temperature was monitored from the thermistor of the pulmonary artery catheter and maintained with a heated mattress.
Circulatior.
The ECG was monitored using the CM5 lead. Radial and pulmonary arterial catheters were inserted under local anaesthesia and the zero was set at the midthoracic level. Cardiac output (CO) was measured by thermodilution in triplicate with less than 10% variation. Derived indices were calculated according to standard formulae. Systolic arterial pressure (SAP) and heart rate (HR) were maintained within 20 % of baseline values throughout the study. Tachycardia and bradycardia were denned as > 100 and < 45 beat min" 1 , respectively. Hypo-or hypertension were denned as SAP < 90 or > 170 mm Hg. Warmed colloid and crystalloid solutions were administered throughout surgery and recovery to maintain pulmonary capillary wedge pressure (PCWP) 1-5 mm Hg greater than baseline values. Tachycardia was treated with propranolol 0.5 mg i.v. every 5 min until HR was consistently less than 100 beat min" 1 . Hypertension was treated with nifedipine 10 mg i.n. repeated every 10-20 min until SAP was consistently less than 170 mm Hg. Hypotension of slow onset was treated with crystalloid 500 ml over 20 min. When hypotension, bradycardia, or both, occurred suddenly, phenylephrine 100 ug, atropine 0.5 mg or both were administered, followed by a volume challenge if the PCWP measured simultaneously was less than the baseline value.
Anaesthesia
Flunitrazepam 20 ug kg" 1 and pancuronium 100 ug kg" 1 were given at induction of anaesthesia. Fentanyl was given at induction (6 ug kg" 1 ), incision (3 ug kg" 1 ) and throughout surgery (4 ug kg" 1 h" 1 ). The total dose of fentanyl was 50 ug kg" 1 in both groups. Seventy percent nitrous oxide in oxygen and pancuronium (as required) were given during maintenance. After operation, patients were sedated with morphine 10 mg s.c, flunitrazepam 1 mg i.v., or both, as required.
Plasma samples
Plasma concentrations of catecholamines were measured in duplicate by a double isotope radioenzymatic technique [11] . The sensitivity of the assay was 25 pg ml" 1 for adrenaline and noradrenaline. Intra-assay coefficient of variation was 8 % and inter-assay coefficient of variation was 12%. Normal values are 30-90 pg ml" 1 for adrenaline and 300-900 pg ml" 1 for noradrenaline in this laboratory.
A radioimmunological assay [12] was used to measure vasopressin (AVP) in duplicate, with a sensitivity of 0.5 pg ml" 1 . Mean (SD) recovery of AVP was 75 (3)%. Intra-assay coefficient of variation was 13% and inter-assay coefficient of variation was 18 %; normal values are 0.5-6.0 pg ml" 1 . Active plasma renin concentration was measured with an immunoradiometric assay (Renin RIA, Diagnostics Pasteur [13] ). The sensitivity was lOpgml" 1 and recovery 97-105%. Intra-assay coefficient of variation was 3.1-6.1% and inter-assay coefficient of variation was 4.8-8.0%; the normal range of values in the recumbent healthy volunteer is 10-25 pg ml" 1 . Plasma concentrations of clonidine were measured with a radioimmunoassay [14] . The detection limit was 10 pg ml" 1 , intra-assay coefficient of variation 4% and inter-assay coefficient of variation 8.3%. Sodium (Na + ) and potassium (K + ) concentrations were measured using indirect potentiometry (Astra Analyzer, Beckmann). Plasma osmolarity was measured by a freezing point depression osmometer (Osmomat 030, Gonotech). Arterial and mixed venous samples were withdrawn simultaneously at a rate of 1.5 ml min" 1 and kept at +4 °C.
Statistical analysis
Data are reported as mean (SD) unless stated otherwise. Clinical data were compared using chisquare test and Wilcoxon's two-sample test as appropriate. Endocrine and circulatory variables were analysed by three methods. Data obtained at baseline and immediately before the beginning of infusion were compared by one-way analysis of variance testing for a treatment effect. Data obtained from the beginning of infusion up to R6 were considered as the postoperative period and compared by analysis of variance for repeated measures, testing for treatment and time factors and their interaction. In the case of significant interaction, the main effect of time was considered at each level of the treatment factor-that is, in each group of patients. In the case of a significant treatment effect, no pairwise comparison at each interval was attempted, as the major aim of the study was to assess the overall evolution of the variables between groups during the postoperative period (from the beginning of infusion to the end of recovery). In the case of non-significant time-treatment interaction, the result of a main effect was considered. Data obtained at baseline and R6 were considered as the perioperative period and compared using identical procedures. P < 0.05 was considered significant.
RESULTS
The groups were similar for patient (table I) , cardiovascular and endocrine variables and intraoperative surgical, anaesthetic and fluid management. There was a greater number of untreated or inadequately treated hypertensive patients in the placebo group, but this was not statistically significant. The number of patients receiving CEB was greater in the placebo group (placebo 11, clonidine 1). Duration of surgery was longer in the placebo group (P < 0.05). However, crossclamp times were similar between groups. Bloodgas tensions, Na + and K + concentrations, osmolarity and temperature were similar in the two groups throughout the study.
Postoperative course
Analgesic/sedative requirements and requirements for fluid volume, atropine or vasopressor treatment were similar between groups (table II). In the placebo group, nine patients presented, before operation with hypertension and 12 patients became hypertensive after operation. In the clonidine group, five patients presented before operation with hypertension and three patients became hypertensive after operation. The clonidine group had a lower incidence of hypertension (P < 0.05), tachycardia, number of nifedipine/propranolol interventions (P < 0.05), total number of vasoactive interventions (P < 0.05) and shivering (table II) . Volume requirements were larger in the clonidine group (total input: clonidine group 1462 (604) ml; placebo group 1064 (348) ml) (P < 0.05). No patient experienced delayed awakening or needed prolonged mechanical ventilation. 14 
Vasoactive hormones
Plasma concentrations of noradrenaline did not change significantly throughout the perioperative period in the clonidine group ( fig. 1 ). Noradrenaline decreased during the infusion of clonidine (P < 0.05, postoperative stages compared with beginning of infusion). In contrast, the placebo group experienced a large increase in noradrenaline (P < 0.001 and P < 0.01 for perioperative and postoperative stages, respectively). This led to a large intergroup difference (P < 0.05 and P < 0.001 for the perioperative and postoperative periods, respectively). Adrenaline concentrations were greater in the placebo group (P < 0.05 for peri-and postoperative periods). However, the increase in adrenaline was not suppressed fully in the clonidine group (P < 0.01 between baseline and R6; no significant difference in the postoperative period). The vasopressin and renin concentrations measured in the clonidine group were 50 % of those measured in the placebo group (P < 0.05 for AVP between groups; not significant for renin between groups). The mean plasma concentration of clonidine in the clonidine group was approximately 2 ng ml" 1 .
Circulatory state
Heart rate decreased in the clonidine group (P < 0.05 and P < 0.01 in the clonidine group for the perioperative and postoperative periods, respectively) ( fig. 2) . Heart rate increased in the placebo group (P < 0.01 within the placebo group for the postoperative period; P < 0.01 between groups). Changes in MAP occurred in the opposite direction in the two groups when perioperative intervals are compared (P < 0.05). The changes in MAP observed after operation in the clonidine group were not significant. An increase in MAP was noted in the placebo group after operation (P < 0.0001); this difference between groups was not significant (P = 0.058). There were no significant differences in calculated systemic vascular resistances. The stroke volume increased in the postoperative period (P < 0.05) in the clonidine group and decreased in the placebo group (P < 0.0001 and < 0.05 for the peri-and postoperative periods, respectively), leading to an intergroup difference (P < 0.01). PCWP was smaller in the clonidine group at baseline only (P < 0.05) ( fig. 2 ).
DISCUSSION
Changes in concentrations of vasoactive hormones and cardiovascular variables in this study were similar to those reported during recovery from coronary [2, 4, 15, 16] or aortic [17, 18] surgery. As cardiac filling and systemic pressures and arterial blood-gas tensions were greater than baseline values or within the normal range, the surge in vasoactive hormones was not primarily a consequence of activation of baroreceptor (except immediately after administration of nifedipine) or chemoreceptor reflexes. This surge may be explained by incomplete postoperative central block despite the intraoperative use of a moderately high dose of fentanyl. This profile could also not be blunted by nifedipine/propranolol. The significance of this incomplete circulatory block and intact endocrine activation is unclear. Circulatory activation, especially tachycardia, is associated with increased coronary morbidity in the setting of coronary surgery [19] . Treatment with conventional therapy [20] or adrenergic inhibitors [21, 22] , reduces mortality and the incidence of perioperative myocardial ischaemia. In contrast, providing the circulation is controlled, the hypothesis that endocrine activation is beneficial rather than harmful may also be considered. This opinion contrasts with the preliminary report that large plasma concentrations of catecholamines are associated with increased morbidity in the present [23] and other [24] [25] [26] circumstances.
The endocrine changes were modified substantially by clonidine, as reported previously for cortisol [27] and catecholamines [2, 4, 6, 7] . Whilst suppression of the adrenaline changes was not complete, noradrenaline concentrations were stable throughout the perioperative period. Given the limitations of plasma noradrenaline as an index of overall sympathetic activity, this observation suggests marked attenuation of hyperactivity. These findings are similar to diose obtained after extradural morphine [18] , except for the reduction of the vasopressin response seen in the present study.
Modification of vasopressin secretion observed in the clonidine group is in agreement with a previous report [9] . The reduction in AVP concentration is similar to that seen after highdose opioids [28] . However, the possibility of highly selective manipulation of the central sympathetic-vasopressin integration [8] in the perioperative period, using a centrally-acting antihypertensive, is at variance [1, 8] with the use of anaesthetics [29] and opioids [28] for this purpose.
Extrapolation of the findings of our study suggests that the smaller changes in HR and MAP observed in the clonidine group combined with the larger stroke volume and lower calculated systemic vascular resistances at similar cardiac output, and the reduced incidence of shivering, might be helpful in reducing the extent of postoperative myocardial ischaemia. However, before considering clonidine as a possible adjunct to conventional postoperative management, several points should be considered. First, more poorly controlled hypertensive patients were included in the placebo group. Thus the difference in mean preoperative arterial pressure [30] could account for much of the difference in arterial pressure observed after operation. In a previous trial with treated hypertensive patients, there was poorer control of preoperative ambulatory arterial pressure and better postoperative control in a clonidine group [3] . Thus the unequal allocation of hypertensive patients is a flaw in this study, but it does not invalidate the findings of attenuation of the hormonal and circulatory responses. Second, clonidine may postpone hormonal activation beyond the first 6 h only. However, the dose of clonidine chosen is known to cause inhibition for at least 12 h beyond the period of study [Quintin, unpublished data] . Third, vasodilator therapy often induces a compensatory increase in vasoconstrictor endogenous compounds, such as angiotensin or thromboxane. An increase in angiotensin is unlikely, as concentrations of both renin and aldosterone are reduced by clonidine [10] .
The effects of a high dose clonidine infusion on the cardiovascular system should be stressed. Cardiac output must be optimized before the infusion is commenced. The infusion rate should be controlled carefully as the tolerance of the cardiovascular system to clonidine is related inversely to its rate of administration [31] . Thus an abrupt reduction in sympathetic activity had to be avoided in view of the high concentration of catecholamines encountered before the infusion.
